Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – The Broch Herald

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), both competing one another are Biotechnology companies. We will contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Demonstrates Rigel Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both businesses.

Risk & Volatility

Rigel Pharmaceuticals Inc.s volatility measures that its 20.00% more volatile than S&P 500 due to its 1.2 beta. In other hand, Brainstorm Cell Therapeutics Inc. has beta of 1.19 which is 19.00% more volatile than S&P 500.

Liquidity

Rigel Pharmaceuticals Inc.s Current Ratio is 5.3 while its Quick Ratio is 5.3. On the competitive side is, Brainstorm Cell Therapeutics Inc. which has a 1 Current Ratio and a 1 Quick Ratio. Rigel Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

In next table is delivered Rigel Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.s ratings and recommendations.

Rigel Pharmaceuticals Inc.s average price target is $6.67, while its potential upside is 178.50%. Competitively Brainstorm Cell Therapeutics Inc. has an average price target of $9, with potential upside of 126.64%. The results from earlier shows that analysts opinion suggest that Rigel Pharmaceuticals Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 96.2% of Rigel Pharmaceuticals Inc. shares and 11.4% of Brainstorm Cell Therapeutics Inc. shares. About 0.25% of Rigel Pharmaceuticals Inc.s share are held by insiders. Competitively, 0.6% are Brainstorm Cell Therapeutics Inc.s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Rigel Pharmaceuticals Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

Summary

Rigel Pharmaceuticals Inc. beats on 8 of the 11 factors Brainstorm Cell Therapeutics Inc.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companys clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continue reading here:
Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald